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                                          ABSTRACT 
 
Investigation of structure- activity relationship have been explored through substitutions at the 
9-position of 2-amino-6-(2-furanyl) purine, to identify novel and selective A2A adenosine 
receptor antagonists. Several potent and selective antagonists were identified. In particular, 
compound 1, with various R substituents show very high affinity with excellent 
selectivity68.In this study, analogs of 2 with substituents in the purine 8-position were 
synthesized. targets compounds are compound 2a, 2b, and 2c. 
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ABBREVIATION 
 
Ac  Acetyl 
AR  Adenosine Receptor 
BuLi  Buthyl lithium 
cAMP  Cyclic-Adenosine monophosphate 
CNS  Central nervous system 
DMF  Dimethylformamide 
Et al.  Et alia (and others) 
EtOAc Ethyl acetate 
EtOH  Ethanol 
GDP  Guanine diphosphate 
GPCR  G-Protein Coupled Receptor 
GTP  Guanine triphosphate 
HMBC Heteronuclear multiple bond correlation experiment 
HMQC Heteronuclear multiple-quantum coherence 
MeOH Methanol 
M.P  Melting point 
MS  Mass spectroscopy 
NaOEt Sodium ethaoxide 
NEt3  Triethylamine 
Ph  Phenyl 
R  Hydrocarbon 
THF  Tetrahydrofuran 
THP  Tetrahydropyran 
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1. 0 Introduction 
 
Purine (Fig. 1) is the most abundant nitrogen-containing heterocycle on earth. The bicyclic 
ring system can be found in many naturally occurring compounds with a wide variety of 
biological roles.                                            
                                                                                                  
                    Fig. 1. The purine ring and the accepted numbering system 
 
Since purines are involved in so many essential biological processes, derivatives have been 
extensively studied as potential drugs and several purines are clinically used as drugs, 
especially as anticancer- and antiviral compounds.3,4 This explains why an active research, 
including herein, focuses on synthesising modified purines as potential drugs or molecular 
tools. Development of metal-mediated reactions for C-C and C-N bond formation has 
facilitated the synthesis of a number of novel purines, many of them with highly interesting 
biological activities. Prominent among the purine nucleoside is adenosine (Fig. 2) and is 
identified as a major local regulator of tissue function especially when energy supply fails to 
meet cellular energy demand.5 
 
1.1 The concept of Receptors 
 
Receptors are site substances in the mammalian body and drug which agonise or antagonise 
neurotransmitters or hormones interact with it. The interaction of these drug substances is 
analogous to lock and key and as such those organic substances which have affinity to these 
receptors, activating it and leading to biological response are classified as agonist whereas 
those organic substances that also have affinity to these receptors but may be as a result of a 
bad conformation, no biological response is elicited are classified as antagonist. But on a 
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general note, any organic substance that have affinity to these receptors can be said to be a 
ligand and as such a ligand in this wise can either be an agonist or an antagonist.  
1.1.1 Adenosine Receptors 
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                      Fig 2. Structure of adenosine                               
Adenosine (Fig. 2) acts as a neurotransmitter in the mammalian nervous system. Because of 
its polar nature and its extremely short half life, most time it is administered intravenously for 
the treatment of some certain acute cardiac condition. The potential of adenosine receptors as 
drug targets was first reviewed in 1982.6 Significant progress has occurred over the last few 
years.7 The regulatory role for adenosine  implicates adenosine based drugs as therapeutic 
targets.6 An improved understanding of the physiology, pharmacology and molecular biology 
of adenosine and adenosine receptors has taken place in recent years. This understanding is 
fundamental to the realisation of the therapeutic potential for this nucleoside and provides a 
solid foundation for the continuation of active research in the adenosine field. Adenosine is a 
signalling substance, which mediate its effects by activation of four different G-protein-
coupled receptors (GPCR) (A1, A2A, A2B and A3).8,9 The adenosine receptors (ARs) belong to 
the rhodopsin family of the GPCR super-family. GPCR is a large membrane bound protein 
which mediates its effects by the activation of an internal guanine nucleotide.10 The 
extracellular region of the protein is composed of the amino terminus and several loops, 
which comprise the ligand-binding site. The carboxyl end of it is located in the part of the 
protein that protrudes inside the cytoplasm.10 The ARs differs in their affinity for adenosine as 
well as their downstream signalling pathways activated in the target cells.                              
The characteristics of the α subunit are what determine the designation of the G protein. 
Receptor activation leads to a conformational change in the associated G protein, triggering 
the release of  bound GDP from the α subunit, which is then replaced by a molecule of GTP.10 
With the binding of GTP, the α-subunits GTP complex dissociates from the αβ subunits and 
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binds to a particular target enzyme, resulting in its activation or inhibition.10 Within a short 
period of time, the α subunit catalyzes the dephosphorylation of the associated GTP molecule 
to GDP, resulting in the reassociation of the α subunit with the αβ subunits and, thus, the 
return of the G protein to the inactivated state.10   
 
1.1.2   Characterisation of adenosine receptor subtypes 
 
Four adenosine receptor subtypes have now been characterised pharmacologically, 
structurally and functionally. These are; A1, A2A, A2B, and A3.10 They are widely distributed in 
various tissues of the body. The A1, A2A and A2B subtypes were initially discovered and 
classified in the classical manner (i.e., by a study of agonist pharmacology).10 Evidence from 
recent cloning, sequencing and expression of each of these subtypes has provided structural 
and functional confirmation of their original classification as distinct adenosine receptor 
subtypes. In contrast, the A3 receptor subtype was discovered by molecular biology studies, 
this was then followed by classical pharmacological studies. All four adenosine receptor 
subtypes have recently been cloned from a variety of mammals, including human.11  
Molecular biology has made significant contributions to adenosine receptor characterisation 
allowing determination of actual receptor protein primary sequences, which is fundamental to 
studying receptor structure, function and regulation at the molecular level.12 
 
1.1.3  Physiological significance of endogenous adenosine 
 
                                             
                                      Figure 3: Naturally occurring xanthines 
The initial realisation of the physiological significance of adenosine was in 1929.13 
Pronounced physiological effects were observed on both cardiovascular and renal function 
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following administration of adenosine to mammals. The clinical evaluation of adenosine in 
man proved disappointing due to the short half-life of adenosine.13 
The ability to study further the physiological role of endogenous adenosine in a variety of 
mammalian tissues followed the discovery that xanthines; caffeine and theophylline, were 
adenosine antagonists.14 Adenosine is now known to regulate a diverse range of physiological 
functions, to the extent that almost all mammalian organ systems are affected by adenosine.15 
The physiological responses to adenosine are complex and depend on the receptor subtype 
activated, the mammalian species, and the type and metabolic state of the tissue.16 
A consequence of the global homeostatic function of endogenous adenosine is the multitude 
of physiological responses mediated by adenosine, presented in Table 1. These responses 
generally lead to a decrease in the oxygen demand and/or increase in the oxygen supply, 
reinstating the energy supply: demand balance within the tissue. One of the most important 
functions of endogenous adenosine is as a cytoprotective agent, preventing tissue damage 
during traumas such as hypoxia, ischaemia, hypotension and seizure activity.26-30 
Table 1. The physiological effects mediated by endogenous adenosine in various mammalian 
tissues, attributed to activation of A1 and A2A receptor subtypes. 
System Physiological effect of endogenous 
adenosine 
CNS Neuromodulator mediating central inhibitory 
effects, inhibits release of neurotransmitters, 
inhibits neuronal firing,  CNS depressant: 
decreases locomotor activity,  anticonvulsant, 
sedation, hypnotic,  antinociceptive,  ataxic,  
mediates respiration.1,2 
Kidney Biphasic modulation of renin release,12 
decreased glomerular filtration rate by 
vasoconstriction  
Adipocytes Inhibits lipolysis (maintenance of body 
weight).48,49  
Immune Immunosuppressant,50,51  inhibits lymphocyte 
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proliferation, anti-inflammatory: Modulating 
neutrophil function. 
Liver Regulates hepaic blood flow,52 stimulates 
gluconeogenesis,59,60  
Stomach Inhibits gastric secretion.36,37  
Straited/smooth muscle Relaxation.38,39  
 
The A2B receptor subtype is a low affinity receptor, adenosine exhibiting activity at this 
subtype at concentrations greater than 10 µM.17,18 There is little information on the 
physiological significance of the A2B subtype, a consequence of the lack of suitably potent 
and selective ligands for detailed study.19 A speculative role for the A2B receptor has been 
proposed.20 It was suggested that the A2B receptor functions during life threatening systems 
failure, reactivating the heart and brain, in order to resuscitate. This action would override the 
protective functions afforded by the A1 and A2A receptors. More recent studies have 
demonstrated that activation of A2B receptors leads to increases in intracellular calcium 
concentrations in cultured cells and chloride ion secretion via cAMP in intestinal epithelial 
cells.21,22 The latter has implications for the treatment of secretory diarrhoea associated with 
inflammation.22] 
The physiological role for the A3 receptor is not adequately understood, a consequence of its 
relatively recent characterisation and a lack of truly selective ligands for in vivo studies. 
Suitably selective and potent ligands (both agonists and antagonists) are being developed 
predominantly by radioligand binding studies, however the relationship between the 
radioligand binding data and selectivity in vivo is not yet established.20 - 23 As well, ligands 
which are already well characterised pharmacologically at the A1 and A2A receptors are being 
characterised at the A3 receptor.24,25 So far this subtype is implicated in mediating a number of 
physiological responses. 
The conclusion from these studies was that the A3 receptor may play a role in mediating 
asthmatic attacks and other allergic responses, however other adenosine receptor subtypes 
have not been ruled out in contributing to the observed responses.26 Using the A3 selective, 
high affinity agonist N6-(3-iodobenzyl)-5′-N-methylcarboxamidoadenosine (3-IB-MECA), in 
vivo studies in mice demonstrated the A3 receptor mediates a locomotor behavioural 
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depressant effect, possibly centrally mediated.31 A cardioprotective role for A3 receptors, 
activating ischaemic preconditioning, has been proposed based on studies in isolated rabbit 
heart.32 N6-2-(4-aminophenyl)ethyladenosine (APNEA) produced a hypotensive response in 
the pithed rat, which was attributed to activation of A3 receptors.33 It was subsequently 
demonstrated that this A3 receptor activation resulted in mast cell degranulation and histamine 
release, implicating the mast cell with a key role in A3 receptor mediated hypotension in the 
rat.34, 35 
1.1.4 Therapeutic potential for drugs acting at adenosine receptors 
The diverse physiological functions of adenosine, outlined earlier, highlight the significant 
benefits of developing therapeutics for the regulation of adenosine receptors. The vast amount 
of effort invested in adenosine research is driven by the therapeutic potential for drugs which 
elicit their actions at adenosine receptors. However, the ubiquitous distribution of adenosine 
receptors in mammalian cell types, the existence of at least four distinct subtypes together 
with the variability of physiological responses means that exploiting this potential requires 
agonists and antagonists that are highly selective in their action (with respect to receptor 
subtype and tissue type) to be of value as therapeutics. 
Successful development of therapeutics is far from trivial. Many promising ligands have been 
identified in the pursuit of therapeutic agents; however side effects due to low selectivity have 
precluded clinical development. The recent cloning of each of the adenosine receptor subtypes 
has allowed, and will continue to allow, the study of receptor subtype structure at the 
molecular level. These studies may identify the discrete differences between subtypes in terms 
of ligand binding requirements, and may prove fundamental to the successful design of not 
only potent ligands but also subtype selective ligands. 
The physiological function of adenosine in the central nervous system (CNS) has been 
extensively researched during the last two decades. Adenosine has been described as a 
neuromodulator, possessing global importance in the modulation of the molecular 
mechanisms underlying many aspects of brain function by mediating central inhibitory 
effects.16,41 An increase in neurotransmitter release follows traumas such as hypoxia, 
ischaemia and seizure activity. These neurotransmitters are ultimately responsible for neural 
degeneration and neural death, which causes brain damage or death of the individual. The 
development of adenosine A1 agonists which mimic the central inhibitory effects of adenosine 
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(and so inhibit neurotransmitter release) may therefore be clinically useful as neuroprotective 
agents.42,43 Adenosine has been proposed to be an endogenous anticonvulsant agent, inhibiting 
glutamate release from excitory neurons and inhibiting neuronal firing.44 Adenosine agonists 
therefore have potential clinical applications as antiepileptic agents. Alkylxanthines, which 
are adenosine antagonists, stimulate the activity of the CNS and have proven to be effective as 
cognition enhancers.45, 32 This is the joint action of antagonism of the sedative effects caused 
by adenosine and of increasing cerebral blood flow, thus increasing glucose and oxygen 
availability to the brain.16 Selective antagonists may have therapeutic potential in the 
treatment of various forms of dementia, for example in Alzheimer’s disease. The pathological 
hallmark of Parkinson’s disease is the depletion of dopamine in the striatum, as a consequence 
of the degeneration of the substantia nigra.40,42 With the knowledge that adenosine inhibits the 
release of dopamine from central synaptic terminals and that A2 agonists reduce locomotor 
activity it was hypothesised that A2 antagonists might increase the release of dopamine and 
consequently improve Parkinsonian symptoms. Theophylline (4), in low doses, produced 
significant improvements in symptoms of patients with Parkinson’s disease, and was 
proposed as a safe adjunct in the therapy of Parkinson’s disease.46 The central activities of 
adenosine are also implicated in the molecular mechanisms underlying sedation, hypnosis, 
schizophrenia, anxiety, pain, respiration, depression and substance abuse. Drugs acting at 
adenosine receptors therefore have therapeutic potential as sedatives, muscle relaxants, 
antipsychotics, anxiolytics, analgesics, respiratory stimulants and antidepressants.43  
Adenosine modulates many aspects of renal function, including renin release, glomerular 
filtration rate and renal blood flow. It plays a role in mediating the haemodynamic changes 
associated with acute renal failure.54 Xanthines, which antagonise the renal affects of 
adenosine, have potential as renal protective agents. Theophylline (4) has been shown to 
improve renal function in humans, preventing acute renal failure caused by iodine-containing 
radiographic contrast media used in X-ray examination. It has also been shown to improve 
renal function after kidney transplantation.55 The xanthine antagonist 1,3-dipropyl-8-(3-
noradamantyl)xanthine (KW-3902), is currently undergoing clinical trials as a renal protective 
agent.56 
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1.2 Structure – activity relationships for ligands at adenosine receptors 
The primary mechanism for studying adenosine receptors, prior to the recent use of molecular 
biology techniques, has been by pharmacological means. A large number of ligands have been 
synthesised and evaluated for adenosine receptor binding affinity. Due to the large number of 
compounds, particularly for the A1 and A2A subtypes, a quite detailed compilation of 
structure–activity relationships has been acquired. These extensive structure–activity 
relationships have enhanced the understanding of the binding domains of adenosine receptors, 
highlighting the key structural features required for receptor affinity and subtype selectivity. 
Also, these structure–activity relationships, together with molecular modelling techniques, 
have been used in the development of a pharmacophore of the ligand binding characteristics. 
With the discovery of the A3 receptor, structure–activity relationships have become more 
complex to interpret and many existing ligands have yet to be evaluated at this subtype. A3 
evaluation is necessary in order to have a complete receptor binding profile for a particular 
ligand. The A2B receptor is not well characterised in terms of structure–activity relationships, 
with just two major structure–activity studies appearing in the literature.57,58 Although these 
studies were known to be at an A2 receptor, it was not until several years later that the 
receptor was characterised as the A2B subtype.18 The recent cloning of the A2B receptor should 
facilitate its future pharmacological study. 
1.2.1 Adenosine receptor agonists 
There exists no novel adenosine receptor agonist structure. All agonists are closely related in 
structure to the endogenous ligand, adenosine 6 (Fig. 2). Structural and stereochemical 
requirements for the ribose moiety of adenosine agonists are strict. Alterations of either 
structure or stereochemistry result in a loss of receptor binding potency and possibly intrinsic 
activity. 
 
1.2.2 Adenosine Receptor Antagonist 
In contrast to agonists, adenosine receptor antagonists are novel in structure compared to 
adenosine. A comparison of different classes of antagonists demonstrates that, although 
diverse in structure, they do share some common structural features. In general the structures 
are: planar,  aromatic or π electron rich; and nitrogen-containing heterocycles.7 There are 
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exceptions to these generalisations, including benzo[b]furan61 and 
tetrahydrobenzothiophenone62 derivatives, with oxygen and sulfur containing heterocycles, 
respectively. The heterocycles are most often 6:5 fused bicyclics or 6:6:5 fused tricyclics, 
substituted with hydrophobic substituents. Additionally, antagonists lack the ribose moiety 
which is essential for agonist activity. 
The first adenosine receptor antagonists reported were the naturally occurring xanthines; 
caffeine (3) and theophylline. (4)14 They exhibited weak affinity and subtype selectivity at 
adenosine receptors. A multitude of xanthines have since been synthesised in the quest for 
potent and selective ligands, and this class have now been optimised to the extent that both 
potent and selective A1 and A2A antagonists exist. More recently xanthines have been 
evaluated at the A3 receptor.23,24 A3 affinity is dependent on species,63  hence structure–
activity relationships become more complex. A3 species differences will be discussed 
separately. 
As is the case for agonists, potent and selective xanthine antagonists stem from multiple 
substitutions of the parent heterocycle. Substitutions at N-1, N-3, N-7 and C-8 of xanthine 
contribute most to potency and selectivity at A1 and A2A receptors.64-66 The structure–activity 
relationships for the N-1 and N-3 substituents of xanthines have been extensively studied at 
A1 and A2A receptors64-66  and to a lesser extent at A3 receptors.23-26 Alkylation at both N-1 and 
N-3 of xanthines is required to maximise adenosine receptor binding affinity at both the A1 
and A2A receptor subtypes, the rank order of potency at both subtypes is methyl < ethyl < n-
propyl ≤ isobutyl. At the rat A3 receptor 1,3-disubstituted xanthines exhibit poor affinity.23, 24  
The most significant enhancements in affinity and subtype selectivity come with substitution 
of the C-8 position of xanthines. C-8 substitution combined with N-1 and N-3 (and sometimes 
N-7) substitution has led to the development of potent and selective A1 and A2A xanthines. 
Potent and selective A2A xanthine antagonists were lacking until recent years. 8-Styryl 
derivatives of 1,3-dimethyl xanthines were found to be highly A2A selective.67  
structurally diverse non-xanthine adenosine antagonists have been identified.7 Unlike 
xanthines the structure–activity relationships for these novel classes of antagonists are not 
well defined, nor have they been optimised to achieve maximal adenosine receptor binding 
affinity or subtype selectivity. Those that are selective are generally A1 selective, with few 
A2A selective ligands.  
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1.3 Approaches, hypotheses and choice of method: 
 
This section deals with previous study, the present study and some synthetic strategies 
explored in the proposed project. 
 
1.3.1 Initial research  
                             
N N
N
N
N
N
NH2
O
O
MeO
5
 
                               Fig. 4. A2A antagonist (SCH-4208147) 
The A2A AR antagonist SCH-420814 5 (Fig. 4 ) is a water-soluble analogue of SCH 58261 6 
(Fig. 5). In compound 7 (Fig. 5), the tricyclic core in SCH 58261 6 (Fig. 5) is replaced by a 
purine ring, still carrying an amino-, a 2-furyl and an arylalkyl group. Several compounds 7 
compared favorably to compound 6 as A2A AR antagonists with respect to potency and 
selectivity (only binding to A1 and A2A were reported).68 Compounds 7 are chemically closely 
related to 6-aryl-9-benzylpurines examined by our group as selective inhibitors of 
Mycobacterium tuberculosis (Mtb) in vitro.69 Some of the most active antimycobacterials  are 
shown in 8 (Fig. 5). It is worth noting that the 6-aryl-9-benzylpurines developed in the 
antimycobacterial project in general displayed very low toxicity towards mammalian cells.69. 
The present study now focused on synthesizing improved selective ligands which are 
structurally related to compound 9.  Analogues of compound 9 with Cl, Me and EtO at the 8-
position are the target compounds. 
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Fig. 5. Structural relationships between A2A antagonists 6 and 7, antimycobacterial 
compounds 8 and target compounds 9. 
 
 
1.3.2 Synthetic strategies 
 
Synthesis was based on literature methods. The 6-aryl substituent was conveniently 
introduced by Pd-catalyzed coupling reactions.69f,71 In the present study, C-8 functionalisation 
of purine intermediates was focused on lithiation and subsequent reaction of lithiated species 
with an electrophiles. Introduction of halogen this way allows further functionalization.69i,69f,72 
However, for instance purine nucleosides are readily lithiated at C-8,72 the reaction may be 
more sluggish with other N-9 substituents.71e  N-9 benzylation was possible by N-alkylation 
using benzylchloride.89 
 
                                                                                                            
Fig. 8. Reaction commonly used in synthesis of targets compounds 
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1.3.3 The Stille reaction 
 
This reaction, discovered by John K. Stille in the 1970’s eventually became known by his 
name, for the coupling of organostannanes with organic electrophiles. The Stille reaction has 
established itself as one of the two most general and most selective palladium-catalysed cross-
coupling reactions along with the Suzuki cross-coupling of organoboron compounds.73 For 
the synthesis of complex molecules, the Stille coupling is usually superior, displaying high 
selectivity and broad scope. Its tolerance towards most functional groups makes the Stille 
coupling particularly effective for transformations of highly functionalized molecules.74 The 
Stille reaction is related to other cross-coupling reactions. Besides the two prominent 
members already mentioned, the family of palladium-catalyzed cross-coupling reactions 
includes the Hiyama,75-78 Sonogashira,79 Kumada,80 and Negishi reactions, 81 
 
Scheme 1. The Stille reaction. 
In his influential review of 1986,82 Stille proposed a mechanism for the Stille reaction based 
primarily on data obtained from the coupling of benzoyl chloride with 
tributyl(phenyl)stannane.82  
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Scheme 2. Generally accepted mechanism of the Stille reaction.83-86 
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1. In the generalized mechanism, the active catalytic species was assumed to be 
palladium0 (PdL2) (L = PPh3) complex, which undergoes oxidative addition with the 
organic halide R-X to form organopalladiumII (Scheme 2).  
2. The organopalladiumII undergoes transmetalation with the organostannane 
(tetraorganotin) compound to give a diorganopalladiumII compound and triorganotin 
halide. 
3. A trans to cis isomerisation, thought to be very fast, was then required for the 
reductive elimination to give the organic product R-R. In this process, palladiumII is 
reduced to palladium0 
 
1.3.4   The Suzuki – Miyaura Cross-Coupling Reaction. 
 
The Suzuki–Miyaura cross-coupling reaction, which involves the coupling of an organoboron 
compound with an electrophile possesses notable advantages over the other related 
techniques. Particularly striking is wide range of functionality tolerated in the coupling 
process. The use of organoboron compounds is also valued because the inorganic by-products 
of the reaction are nontoxic and can be readily removed by simple workup procedures, while 
many tin compounds are toxic, and complete removal of tin-containing by-products are a 
well-recognized problem. 
Because of their commercial availability, boronic acids are most often utilized in Suzuki– 
Miyaura cross-coupling reactions. However boronic acids exhibit several limitations that 
make them unattractive nucleophilic coupling partners. Boronic acids are not monomeric 
materials, but rather exist in equilibrium with dimmers and cyclic trimers (boroxines).101 
consequently, many boronic acids are waxy solids that are difficult to purify. Most 
importantly, many boronic acids, and especially electron-deficient heteroarylboronic acids, 
have a short shelf life due to their tendency to undergo facile protodebronation. This 
instability often requires their storage at low temperatures. The tendency to protodeboronate 
quite often manifests itself during cross-coupling reactions carried out in polar protic 
solvents.102 The protodeboronation influences the stoichiometry of the reaction. 
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Scheme 3 
In this study, a greener approach which employs the use of potassium organotrifluoroborates 
as coupling partners for the Suzuki – Miyaura reaction103 (Scheme 3) was attempted.  
 
1.3.5     N-Alkylation of purines. 
The unsubstituted purine can exist in four possible tautomers (Scheme 4). The ratio of these 
tautomers depends on the state of the purine. In crystalline state, it exists as a 7H-tautomer. 
Both 7H- and 9H-tautomers exist in approximately equal amounts in solution; while 1H- and 
3H tautomers are insignificant.90 
 
 
Scheme 4. Different tautomers of purines 
Using a base enhances the reaction of purine nitrogen with electrophilic alkylating agents. 
The purine N-hydrogen is acidic and can be removed by a base forming a more reactive 
species. The anionic form can exist in any of the four tautomers (Scheme 4). 
Alkylation can take place on any of the ring atoms. The position of alkylation  is however 
affected by the substituent on the ring atom and the nature of the alkylating agent. For 
instance adenine gives 3-alkylated products under neutral conditions but 7/9-substitution 
results under basic conditions89 while adenosine derivatives usually give the 1-alkylated 
products which is assumed to be due to hindrance to the N-3 position.90 From this example, it 
can be deduced that with electron donating group in the six member ring, the ring is activated 
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towards electrophiles. But with electron withdrawing group in the six member ring for 
example the 6-chloropurines, reactivity is directed to the five member ring forming the N-7 
and N-9 products the ratio of which depends on the alkylating agents. The major product in 
most cases is the N-9substituted product. Benzyl halide alkylating agents give mainly the N-9 
product as the major product for 6-chloropurine90 which is assumed to be due to steric 
hindrance from the 6-chloro group which interferes the formation of N-7 alkylated isomer. 
This goes to say that the ratio of N-9 to the N-7 alkylation is greatly influenced by the size of 
the substituent in the 6-position.90 
In difficult situation where N-7/N-9 selectivity is poor, alkylation can be directed to the N-9 
by using a bulky protecting group in the C-6 position Scheme 5.90  
 
Scheme 5. 
 
      1.3.6 Lithiation-based electrophilic substitution at the purine 8-position 
 
Purine 8- position is unreactive towards electrophiles. However, purinyl anions derived 
via lithiation can react readily with electrophiles like hexachloroethane (Scheme 6). 8- 
halo purines accessible by this route can be used for further functionalization like 
nucleophilic substitution.91-94 Alkylation at 8-position can also be achieved by reaction of 
organolithium intermediates with alkylating agents e.g. iodomethane. The lithiation is 
mostly carried out using lithium amide. 
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Scheme 6 
Lithium amide compounds particularly lithium amides (R2NLi)n, are commonly used as 
strong bases in organic synthesis. The ability of these species as reagents, especially 
where the organic groups (R) are bulky, relies mainly on their low nucleophilicity 
compared with C-Li bonded complexes (e.g. MeLi). These properties cause proton 
abstraction to be favoured over nucleophilic addition. Such deprotonation reaction can 
also be regio and/or enantiospecific.95 One of such commonly used lithiation agents is 
lithium diisopropylamide (LDA). LDA has been indicated by Kato et al.96 and Tanaka et 
al.97 as a better lithiating agent compared with butyllithium for regioselective lithiation at 
position-8 (illustrated in Scheme 7). It can cause lithiation in position-8 even in the 
presence of a halogen (e.g. chlorine) in the 6-position. When butyllithium was used for the 
same reaction there was nucleophilic addition of butyl to form 8-butylated purine and a 
lithium-halogen exchange forming a butyl chloride and a 6-lithiated purine.98  
 
Scheme 7 
The exact mechanism of the metallation (lithiation) is not known, but it is thought to 
involve a four centre transition state (Scheme 8).90 In the lithiation process although a 
‘free anion’ is never formed, the ease of lithiation correlates well with the C-hydrogen 
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acidity and of course this, with the stability of the corresponding conjugate base 
(carbanion).90  
 
Scheme 8 
The acidity of N-9 and N-7 hydrogen makes it important to protect this position before 
lithiation (using strong base such as LDA) can take place at C-8.90 This however does not 
seem to be always the case since all attempts made by Nolsøe et al. to lithiate 6-chloro-9-
benzypurine failed.100  Therefore attached substituents in the imidazole ring depending on 
their nature can affect the C-hydrogen acidity in the ring either by inductive or mesomeric 
effect.99 
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2.0 RESULTS AND DISCUSSION 
 
2.1 SYNTHESIS OF TARGET MOLECULES. 
 
Synthesis of the following target molecules is discussed in this section 
• 9-Benzyl-6-(furan-2-yl)-8-methyl-9H-purin-2-amine (44a) 
• 9-Benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a) 
• 9-Benzyl-6,8-di(furan-2-yl)-9H-purin-2-amine (43a) 
• 9-Benzyl-8-ethoxy-6-(furan-2-yl)-9H-purin-2-amine (45) 
 
Scheme 9. Possible Routes to synthesis target compounds. 
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Above (Scheme 9) shows roughly, the possible routes to approach this synthesis starting from 
the commercially available 6-chloro-9H-purin-2-amine (29). Among these possible synthetic 
routes to the target compounds, routes with thick black arrows were preferred because of the 
following reasons 
• Routes f and i were avoided because Synthesising compounds 35a and 37 via route h 
may lead to lithiation in the furyl ring which was observed as earlier reported.69i 
• Route j was avoided because routes k and m may be unsuccessful since all attempts 
made by Nolsøe et al. to lithiate 6-chloro-9-benzylpurine failed.100 
• Route e was preferred to route o because the 6-fuyl substituents which is larger in size 
than the 6-chloro substituents may influence the increase in the percentage of 9- versus 
7-alkylation.90 This was the reason why route p was not attempted. 
2.1.1  6-Chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (31). 
 
As stated ealier, the acidity of N-9 and the amino hydrogens makes it important to protect this 
positions before proceding with lithiation. This was achieved by reacting 6-chloro-9H-purine-
2-amine (29) with 3,4-dihydro-2H-pyran (30) using HCl in DMF as catalyst (Scheme 10). The 
product compound (31) was isolated in moderate yield 55% compared to the yield reported in 
literature 71%.104 The reaction conditions, solvent, temperature, time, etc, chosen for this 
reaction were the same as those used in earlier report.104 
 
Scheme 10. Reagents and conditions: a – 2M HCl in DMF (0.1 eq,), DMF, 60oC, 2 hr 
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2.1.2 6-Chloro-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (32) and 6,8-dichloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (33). 
 
6-Chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (31) was lithiated  at C-8 
using LDA and trapped with methyl iodide or hexachloroethane69i to give compounds 32 and 
33 respectively. These reactions yielded only the desired products (Scheme 11). 
 
 
Scheme 11. Reagents and conditions: (a) LDA, THF, -78 oC; (b) CH3I (10 eq), THF, -78 oC 
(c) C2Cl6 (2 eq), THF, -78 oC. 
2.1.3  8-Chloro-6-(furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-
2-amine (35a).  
 
Compound 33 was subjected to Stille coupling using Pd2dba3  and 2-furyl)3P as catalyst  to 
give the furylpurines (35) (Scheme 12). Complete conversion was not obtained under mild 
conditions,69f also moderate amount of dicoupled product 35b was formed. The 1H NMR 
spectrum of the crude reaction mixture showed the distribution to be 35a : 35b : 33; 4 : 2 : 1 
and the products 35a : 35b : 33; were isolated in 43%, 19% and 13% yield respectively. 
Increase in temperature resulted in better conversion at expense of  selectivity (Table 2) as 
compounds 35a and 35b were formed in almost in the ratio of 1:1 as judged from the crude 
NMR. We envisioned that sterical hindrance near C-8 position would push the selectivity 
towards C-6 if a bulkier ligand like PdCl2(dppf) is used. But the increase in yield was not 
significant (Table 3).  
The tributyl tin chloride (Bu3SnCl) present in the crude reaction mixture can be removed by 
stirring the crude mixture with an alcoholic solution of KF, leading to the formation of 
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insolouble trialkyl fluorides,88,87 which can then be removed by flash chromatography. KF-
MeOH treatment was avoided during work-up of this synthesis because the product 35a 
contains a good leaving group which can result to nucleophilic substitution and the 
introduction of a methoxy group.89,70 KF-THF treatment was rather preferred. Despite this 
attempt, tributyl tin chloride formed in this transformation could not be completely removed. 
In further attempts, crude reaction mixture was partitioned between MeCN and hexane, 
repeated washings of MeCN layer with hexane allowed removal of lipophilic tributyl tin 
chloride. 
Scheme 12. Reagents and conditions. a- Pd Cat. DMF. 
Table 2: Yields of products using Pd2dba3 (0.03 eq) and 2-furyl)3P (0.2 eq) as Catalyst . 
Temperature (oC) Compounds Yield (%)  
 
50 35a 43 
35b 19 
33 13 
60 35a 40 
35b 36 
33 0 
 
Table 3: Yield of products using pdCl2.dppf.CH2Cl2 (0.04eq) as catalyst. 
Temperature (oC) Compounds Yield (%) 
50 35a 32 
35b 18 
33 26 
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Determined  to improve the yield of these reactions a greener approach which employs the use 
of potassium organotrifluoroborates (36) as coupling partners for the Suzuki – Miyaura 
reaction103 (Scheme 13) was attempted.  
 
Scheme 13:  Reagents and conditions: a – 1 mol % Pd(OAc)2, 2 mol %Et3N, 2 equiv Na2CO3 
ethanol, 50oC 
Table 4: Comparison between Stille and Suzuki at 50 oC 
Compound Stille (Yield %) Suzuki (Yield %) 
35a 43 34 
35b 19 20 
33 23 12 
 
However, no improvement was observed using Suzuki, but rather there was a little decrease in 
the yield of the product (Table 4). Moreover, it seems logical to use Stille coupling for this 
transformation, because at higher temperature, C-8 and / or C-6 halo purine are prone to 
nucleophilic attack by nucleophilic solvents like ethanol. Further optimisation of these 
conditions was not done. 
 
 
 
23 
 
2.1.4  6-(Furan-2-yl)-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-
purin-2-amine. (37) 
N
N N
N
Cl
N
H
O
O
32
O
SnBu3
N
N N
N
N
H
O
O
34
a
O
37
2 eq
 
Scheme 14. Reagent and conditions. Pd-Cat, DMF, 90 oC 
In this transformation (Scheme 14), a reactive catalyst PdCl2.dppf.CH2Cl2 was required in 
order to achieve complete conversion. (Table 5), and compound 37 was isolated at good yield 
68%.  
Table 5 
Catalysts Compounds Yield (%) 
Pd2dba3 (0.03 eq) and 2-
furyl)3P (0.2 eq) 
37 35 
32 15 
pdCl2.dppf.CH2Cl2 (0.05 
eq) 
37 68 
32 0 
 
 
2.1.5. 6-(Furan-2-yl)-8-methyl-9H-purin-2-amine (40), 8-Chloro-6-(furan-2-
yl)-9H-purine-2-amine (38) and 6,8-di(furan-2-yl)-9H-purin-2-amine (39). 
 
Compound 35a, 35b and 37 was deprotected to give compounds 38, 39, and 40 respectively 
(Scheme 15). This transformation resulted to the desired product. Longer reaction time was 
required for complete deprotection to compounds 38, and 39 for reasons not understood.  
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Scheme 15: Reagents and condition: a – 9.6 M HCl, EtOH, rt. 
 
2.1.6   9-Benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a), 9-benzyl-6-
(furan-2-yl)-8-methyl-9H-purin-2-amine (44a) and 9-benzyl-6,8-di(furan-2-
yl)-9H-purin-2-amine (43a). 
 
6-(Furan-2-yl)-8-methyl-9H-purin-2-amine(40), 8-chloro-6-(furan-2-yl)-9H-purine-2-
amine(38) and 6,8-di(furan-2-yl)-9H-purin-2-amine(39) were N-alkylated with benzyl 
chloride  (41) in the presence of potassium carbonate. (Scheme 16). 
N
N N
H
N
O
H2N
X ClCH2Ph
(1.5 eq)
N
N N
N
O
H2N
X
N
N N
N
O
H2N
X
38 X = Cl
39 X = Furyl
40 X = CH3
41
42a X = Cl, f rom 38, 45%
43a X = Furyl, f rom 39, 53%
44a X = CH3, f rom 40, 65%
42b X = Cl 25%
43b X = Furyl, 21%
44b X = CH3, impure
a
Scheme 16. Reagents and condition. a - K2CO3 (3eq), DMF, rt 
Both the N-9 and N-7 benzylated isomers were formed with the latter as the minor isomer but 
the N-7 isomers; 44b was not isolated pure due to problems encountered during separation. 
Also a small amount of disubstitution 42c was observed in the formation of compound 42a. 
The 1H NMR spectrum of the crude product showed the isomer distribution to be 42a : 42b; 
2:1, 43a : 43b; 3:1, 44a : 44b; 2:1. The change in the ratio 43a : 43b could be attributed to the 
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more bulky furyl groups in the 6 and 8 positions which could constitute sterical hindrance to 
the formation of N-7 isomer. 
 
 
 
2.1.7  9-Benzyl-8-ethoxy-6-(furan-2-yl)-9H-purin-2-amine (45). 
 
By using 8-halopurines relatively easy nucleophilic attack takes place at 8-position with a 
wide range of nucleophiles such as alkoxide, sulphides, amines, azide, cyanide, and malonate 
and related carbanions.90 Compound 42a was subjected to nucleophilic substitution reaction 
with sodium ethoxide to afford the introduction of ethoxy group in this position (Scheme 17). 
In this reaction, desired product 45 was formed in 63% yield. 
 
 
Scheme 17: a – NaOEt in EtOH (0.216 M), 15 h, rt 
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3.0 Conclusion. 
All the three target compounds were successfully synthesised and have been submitted for 
biological testing together with the N-alkylated dicoupled Product (43a).  In this study we 
want to apply existing models for the ARs and perform docking studies of ligands with 
selective affinity for the various ligands with the purpose of designing more potent and 
selective ligands. These studies will be carried out by the groups of Prof. Christa Müller and  
collaborators especially Dr. Astrid Maaß at the Fraunhofer Institute, SCAI, St. Augustin 
Germany.  
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4.0 EXPERIMENTAL 
 
The 1H NMR spectra were recorded at 300MHz with Bruker DRX 300  or at 200 MHz with 
Bruker DPX 200 intrument, The 13C NMR spectra were recorded at 75MHz using Bruker 
DRX 300 instrument. Mass spectra were recorded by electron ionization at 70eV ionizing 
voltage and are presented as m/z (% relative intensity). The chemical shifts (δ) are given in 
ppm. THF and DMF were obtained from automated solvent drying system. Diisopropylamine 
was distilled from CaH2. Melting points were determined with a Büchi melting point B-545 
apparatus and are uncorrected. Elemental analysis were performed at School of Chemistry, 
University of Birmingham, Edgbaston, Birmingham. All other reagents were commercially 
available and used as received.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
4.1 Synthesis of 6-Chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (31). 
                                                     
                                                                31 
To a mixture of 6-chloro-9H-purin-2-amine (29) (170 mg, 1 mmol) in DMF 10 mL, 2M HCl 
in DMF (50 µl, 0.1 mmol) was added and the mixture was stirred at 60 oC for 5 min and then 
3,4-dihydro-2H-pyran (30) (0.45 mL, 5 mmol) was added dropwise. The stirring was 
continued at 60 oC for 2h and the solvent was evaporated. A column chromatography (silica 
gel, EtOAc: hexane 3:1) of the crude, afforded the protected derivative. 
Yield  216mg (63%) Colourless Powder 
M.P. 170 – 172 oC 
1H NMR (DMSO-d6, 300 MHz): δ 1.42 – 1.96 (m, 12H, CH2 in THP), 3.44 – 4.01 (m, 4H, 
OCH2 in THP), 5.14 (br s, 1H, THP), 5.52 (d, J = 10.7Hz, 1H, THP), 8.08 (d, J = 8.8 Hz, 1H, 
NH), 8.38 (s, 1H, H-8). 
13C NMR (DMSO-d6, 75 MHz): δ 23.26, 25.32 , 25.81, 30.39, 30.48, 31.07 (CH2 in THP), 
66.42 (OCH2 in THP), 68.55 (OCH2 in THP), 80.87 (CH in THP), 81.94 (CH in THP), 125.05 
(C-5), 142.68 (C-8), 150.42 (C-6), 154.04 (C-4), 158.49 (C-2)    
MS EI, m/z (rel. %): 337 ( 8, M+), 253(17), 169 (100), 85 (61)  
HR-MS: Found 337.129800, calculated value for C15H20ClN5O 2   337.1382 
. 
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Spectrum 1.1H NMR of 6-Chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (31). 
Spectrum 2. 13C NMR of 6-Chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine 
(31). 
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Spectrum 3. HMQC of 6-Chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (31). 
 
Spectrum 4. HMBC of 6-Chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (31). 
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4.2  Synthesis of 6-Chloro-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-
purin-2-amine (32). 
                                                      
                                                                        32 
 A solution of diisopropylamine (2.2 mmol 0.3 ml) in dry THF (4 mL) was stired at -78oC 
under N2. n-BuLi (1.25 mL, 2 mmol, 1.6 M in hexane) was added dropwise. After stiring for 
20 min, a solution of 6-chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (31) (1 
mmol, 0.338 g) in THF (4 mL) was added. After additional stirring for 1 h at -78oC, 
iodomethane (0.62 mL, 10 mmol) was added dropwise and the resulting mixture was stirred at 
-78oC for 3.5 h, gradually warmed to ambient temperature over 2 h and stirred at ambient 
temperature for 15 h. work up: Sat aqNH4Cl (30 mL) was added and the mixture was 
extracted with EtOAc (2 x 50 mL). the combined organic extracts were washed with brine (40 
mL), dried (MgSO4) and evaporated in vacuo. The product was purified by flash 
chromatography on silica gel eluting with a EtOAc/hexane mixture (5:1) . 
Yield 310 mg, (90%), Pale yellow solid. M.p 184 – 186 oC, 
 
1H NMR (DMSO- d6, 300 MHz):  δ  1.42 – 1.95 (m, 12H, THP), 2.55 (s, 3H, CH3), 3.40 – 
4.04 (m, 4H, THP), 5.09 (br s, 1H, THP), 5.49 – 5.53 (m, 1H, THP), 7.94 (d, J = 7.1 Hz, 1H, 
NH).  
13C NMR (DMSO- d6, 75 MHz): δ  15.99 (CΗ3), 23.41, 23.55 , 25.48, 25.84, 29.42, 30.99 
(CH2 in THP), 66.47 (OCH2 in THP), 68.84 (OCH2 in THP), 81.00 (CH in THP), 83.36 (CH 
in THP), 124.02 (C-5), 148.67 (C-6), 152.71 (C-8), 155.47 (C-4), 157.80 (C-2).    
MS EI m/z (rel. %): 353/351 (3/9, M+), 267 (15) , 183/185 (37/100), 148 (8)  
HR-MS: Found 351.145160, calculated value for C16H22ClN50 2   351.1462. 
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Spectrum 5. 1H NMR of 6-Chloro-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (32). 
 
Spectrum 6. 13C NMR 6-Chloro-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (32). 
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Spectrum 7. HMQC of 6-Chloro-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine(32). 
 
Spectrum 8. HMBC of 6-Chloro-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (32). 
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4.3 Synthesis of 6,8-dichloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-
2-amine (33). 
                                                         
                                                                                 33 
A solution of diisopropylamine (0.81 mL, 5.94 mmol) in dry THF (10.8mL) was stired at -
78oC under N2. n-BuLi (5.4 mL, 5.4 mmol, 1.0 M in hexane) was added dropwise. After 
stirring for 20 min, a solution of 6-chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (31) (1 g, 2.7 mmol) in THF (10.8mL) was added. After additional stirring for 1 h at -
78oC, a solution of hexachloroethane (1278 mg, 5.4 mmol) in THF (10.8 mL) was added 
dropwise and the resulting mixture was stirred at -78oC for 2 h, and 10 min without cooling, 
sat aq NH4Cl (81 mL) was added and the resulting mixture was extracted with EtOAc (2 x 
135 mL). The combined organic extracts was washed with brine (108 mL), dried with MgSO4 
and evaporated in vacuo. Product was purified by flash chromatography on silica gel eluting 
with EtOAc/hexane mixture (1:1) 
Yield 0.91 g, (91%) yellow powder. M.p 140 – 142 oC,  
1H NMR (DMSO- d6, 300 MHz): δ 1.56 – 1.97 (m, 12H, THP), 3.40 – 4.05 (m, 4H, THP), 
5.07  (br s, 1H, THP), 5.52 – 5.56  (m, 1H, THP), 8.23 (br s, 1H, NH).  
13C NMR  (DMSO- d6, 75 MHz): δ  23.34, 23.43, 25.38, 25.79, 28.49, 30.87 (CH2 in THP), 
66.54 (OCH2 in THP), 68.90 (OCH2 in THP), 80.98 (CH in THP), 84.22 (CH in THP), 123.52 
(C-5), 140.25 (C-4), 149.35 (C-6), 154.86 (C-8), 158.20 (C-2).    
MS (EI) m/z (rel. %): 375/373/371 (2/8/13, M+), 291/289/287 (5/30/45), 207/205/203 
(18/79/100), 168 (13)   
HR-MS: Found 371.091962, caculated value for C15H19Cl2N5O2 371.0916  
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Spectrum 9. 1H NMR of 6,8-dichloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (33). 
 
Spectrum 10. 13C NMR of 6,8-dichloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (33). 
 
 
36 
 
Spectrum 11. HMQC of 6,8-dichloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (33). 
 
Spectrum 12. HMBC of 6,8-dichloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (33). 
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4.4 Synthesis of 6-(Furan-2-yl)-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-
yl)-9H-purin-2-amine (37). 
 
                                                         
                                                                   37 
2-furyl (tributyl) tin (34) (0.53 mL, 1.66 mmol) was added to a solution of 6-chloro-8-methyl-
N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (32) (290 mg, 0.83 mmol) and 
pdCl2.dppf.CH2Cl2 (52 mg, 0.04 mmol) in DMF (9 mL). The resulting mixture was stirred at 
90oC under N2 for 16 h, cooled and evaporated in vacuo. Crude reaction mixture was 
partitioned between Acetonitrile (30 mL) and hexane (10 mL), repeated washings of MeCN 
layer with hexane allowed removal of lipophilic tributyl tin chloride. The product was 
purified by flash chromatography on silica gel eluting with EtOAc/hexane (1:1). 
Yield 215 mg, (68 %), colourless powder. M.p 155 – 157oC,  
1H NMR (DMSO- d6, 300 MHz): δ 1.44 – 1.98 (m, 12H, THP), 2.60 (s, 3H, CH3), 3.42 – 
4.03 (m, 4H, THP), 5.23  (br s, 1H, THP), 5.55 – 5.58 (m, 1H, THP), 6.73 (dd, J = 3.3, 1.7 
Hz, 1H, H-4 in furyl), 7.57 (br, s, 1H, NH), 7.67 (d, J = 3.24 Hz, 1H, H-3 in furyl), 7.95 (s,   
H-5 in furyl). 
13C NMR  (DMSO- d6, 75 MHz): δ 16.18 (CH3) 23.68, 25.55, 25.94, 29.65, 31.17, 31.27 
(CH2 in furyl), 66.49 (OCH2 in THP), 68.78 (OCH2 in THP), 81.20 (CH in THP), 82.96 (CH 
in THP), 113.26 (C-4 in furyl), 116.90 (C-3 in furyl), 122.30 (C-5), 144.74 (C-6), 146.23 (C-5 
in furyl), 150.47 (C-2 in furyl) 151.77 (C-8), 155.38 (C-4), 158.11 (C-2), 
 MS (EI) m/z (rel %): 383 (10, M+), 299 (11), 215 (100), 199 (5),  147 (2) 
HR-MS: Found 383.2019, caculated value for C20H25N5O3 383.1957 
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Spectrum 13. 1H NMR of 6-(Furan-2-yl)-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (37). 
 
.  
Spectrum 14. 13C NMR of 6-(Furan-2-yl)-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (37). 
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Spectrum 15. HMQC of 6-(Furan-2-yl)-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (37). 
 
Spectrum 16. HMBC of 6-(Furan-2-yl)-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (37). 
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4.5 Synthesis of 8-Chloro-6-(Furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-
yl)-9H-purin-2-amine (35a) and 6,8-di(furan-2-yl)-N,9-bis(tetrahydro-2H-
pyran-2-yl)-9H-purin-2-amine (35b). 
 
                                      
                                    35a                                                               35b 
A mixture of tris (diphenylmethylideneacetone) – dipalladium chloroform adduct (66 mg, 
0.062 mmol) and tri (2-furyl) phosphine (105 mg, 0.45 mmol) in DMF (25 mL) was stirred at 
ambient temperature under N2 for 15 min, before 6,8-dichloro-N,9-bis(tetrahydro-2H-pyran-2-
yl)-9H-purin-2-amine (33) (780 mg, 2.1 mmol) and 2-furyl (tributyl) tin (34)  (0.8 mL, 2.52 
mmol) were added. The resulting mixture was stirred for 18 h at 50oC and evaporated. The 
residue was dissolved in acetonitrile (80 mL) and washed with hexane (15 X 25 mL). The 
acetonitrile layer was evaporated and the products were isolated by flash chromatography on 
silica eluting with EtOAc/hexane (1:2) followed by EtOAc/hexane (1:1). 
 
4.6 Synthesis of 8-Chloro-6-(Furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-
yl)-9H-purin-2-amine (35a). 
 
Yield 360 mg, (43 %), Colourless powder. M.p 162 – 164 oC, 
1H NMR (DMSO- d6, 300 MHz): δ 1.44 – 1.99 (m, 12H, THP), 3.42 – 4.06 (m, 4H, THP), 
5.19  (br s, 1H, THP), 5.56 – 5.59 (m, 1H, THP), 6.75 (dd, J = 3.3, 1.7 Hz, 1H, H-4 in furyl), 
7.62 (d, J = 3.4 Hz, 1H, H-3 in furyl), 7.87 (br, s, 1H, NH), 8.00 (s,   H-5 in furyl). 
13C NMR  (DMSO- d6, 75 MHz): δ 23.60, 25.44, 25.89, 28.63, 31.01, 31.13 (CH2 in THP), 
66.54 (OCH2 in THP), 68.90 (OCH2 in THP), 81.13 (CH in THP), 83.85 (CH in THP), 113.50 
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(C-4 in furyl), 117.57 (C-3 in furyl), 121.61 (C-5), 139.20 (C-4), 145.56 (C-6), 146.92 (C-5 in 
furyl), 149.74 (C-2 in furyl), 154.97 (C-8), 158.59 (C-2), 
 MS (EI) m/z (rel. %): 405/403 (2/6, M+), 321/319 (8/24), 237/235 (36/100), 85 (13).  
HR-MS: Found 403.141679, calculated value for C20H25N5O3 403.1411. 
 
 
 
 
Spectrum 17. 1H NMR of 8-Chloro-6-(Furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-
purin-2-amine (35a). 
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Spectrum 18. 13C NMR of 8-Chloro-6-(Furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-
purin-2-amine (35a). 
 
Spectrum 19. HMQC of 8-Chloro-6-(Furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (35a). 
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Spectrum 20. HMBC of 8-Chloro-6-(Furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-
purin-2-amine (35a). 
 
4.7 Synthesis of 6,8-di(furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-
purin-2-amine (35b). 
 
Yield 200 mg, (19 %), dark-yellowish powder. M.p 154 -157 oC 
1H NMR (DMSO- d6, 300 MHz): δ 1.45 – 2.06 (m, 12H, THP), 3.43 – 4.11 (m, 4H, THP), 
5.22  (br s, 1H, THP), 5.79 (d, J = 10.7Hz, 1H, THP), 6.77 (br s, 2H, H-4 in furyl), 7.21 (d, J 
= 3.0 Hz, 1H, H-3 in furyl), 7.78(d, J = 3.4, 1H, H-3 in furyl), 7.84 (br, 1H, NH), 8.01 (s, 2H   
H-5 in furyl). 
13C NMR  (DMSO- d6, 75 MHz): δ 23.69, 23.79, 25.46, 25.94, 28.74, 31.19 (CH2 in THP), 
66.57 (OCH2 in THP), 68.71 (OCH2 in THP), 81.31 (CH in THP), 84.16 (CH in THP), 113.08 
(C-4 in furyl), 113.47 (C-4 in furyl) 114.96 (C-3 in furyl), 117.76 (C-3 in fu 
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ryl), 123.13 (C-5), 143.32 (C-4), 143.45 (C-6), 144.58 (C-2 in furyl), 146.35 (C-5 in furyl) 
146.66 (C-5 in furyl), 150.152 (C-2 in furyl), 155.38 (C-8), 158.55 (C-2). 
MS (ESI) m/z (rel. %): 436 (50, M+), 352 (100) 
HR-MS: Found 435.190079, caculated value for C23H25N5O4 435.1907. 
 
 
Spectrum 21. 1H NMR of 6,8-di(furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (35b). 
. 
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Spectrum 22. 13C NMR of 6,8-di(furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (35b). 
 
Spectrum 23. HMQC of 6,8-di(furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (35b). 
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Spectrum 24. HMBC of 6,8-di(furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (35b). 
 
4.8 Synthesis of 8-Chloro-6-(furan-2-yl)-9H-purin-2-amine (38). 
 
N
N
H
N
N
H2N
Cl
O
 
                38 
A mixture of 8-chloro-6-(furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine 
(35a) (320 mg, 0.8 mmol), 96% EtOH (14 mL) and 9.6 M HCl (0.84 mL) was stirred at 
ambient temperature until TLC shows complete conversion and neutralized by addition of 
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solid KHCO3. The resulting mixture was evaporated in vacuo and the product was isolated by 
flash chromatography on silica gel using Chloroform/MeOH (50:1).  
Yield 165 mg, (88 %), Yellowish powder. M.p 167 – 169 oC, 
1H NMR (DMSO- d6, 300 MHz): δ 6.54 (s, 2H, NH2), 6.73 (dd, J = 3.3, 1.7 Hz, 1H, H-4 in 
furyl), 7.56 (d, J = 3.27 Hz, 1H, H-3 in furyl), 7.95 (d, J = 0.9 Hz, H-5 in furyl), 13.40 (br, 
1H, NH). 
13C NMR  (DMSO- d6, 75 MHz): δ 113.37 (C-4 in furyl), 116.77 (C-3 in furyl), 121.99 (C-5), 
139.47 (C-4), 144.31 (C-6),  146.46 (C-5 in furyl), 150.02 (C-2 in furyl), 157.03 (C-8) 160.67 
(C-2), 
MS (EI) m/z (rel. %): 237/235 (32/100, M+) 
HR-MS: Found 235.025732, caculated value for C9H6ClN5O 235.0261. 
 
 
Spectrum 24. 1H NMR of 8-Chloro-6-(furan-2-yl)-9H-purin-2-amine (38). 
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Spectrum 26. 13C NMR of 8-Chloro-6-(furan-2-yl)-9H-purin-2-amine (38). 
 
Spectrum 27. HMQC of 8-Chloro-6-(furan-2-yl)-9H-purin-2-amine (38). 
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Spectrum 28. HMBC of 8-Chloro-6-(furan-2-yl)-9H-purin-2-amine (38). 
 
 
4.9 Synthesis  of 6-(Furan-2-yl)-8-methyl-9H-purin-2-amine (40). 
 
                                                              
A mixture of 6-(furan-2-yl)-8-methyl-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine 
(37) (150 mg, 0.4 mmol), 96% EtOH (7 mL) and 9.6 M HCl (0.4 mL) was stirred at ambient 
temperature until TLC shows complete conversion and neutralized by addition of solid 
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KHCO3. The resulting mixture was evaporated in vacuo and the product was isolated by flash 
chromatography on silica gel using Chloroform/MeOH (50:1).  
Yield 82 mg, (95 %), Yellowish powder. M.p 151 – 154 oC, 
1H NMR (DMSO- d6, 200 MHz): δ  2.45 (s, 3H, CH3), 6.24 (br s, 2H, NH2), 6.71 (dd, J = 3.4, 
1.7Hz, 1H, H-4 in furyl), 7.56 (d, J = 2.3, 1H, H-3 in furyl), 7.91 (dd, J =  1.66, 0.94 Hz, 1H, 
H-5 in furyl), 12.39 (br, 1H, NH) 
13C NMR  (DMSO- d6, 75 MHz): δ 15.80 (CH3) 113.14 (C-4 in furyl), 116.60 (C-3 in furyl), 
145.77 (C-5 in furyl), 150.93 (C-2 in furyl), 160.56 (C-2), 
MS (EI) m/z (rel. %): 215 (100, M+) 
HR-MS: Found 215.080198, caculated value for C10H9N5O 215.0807. 
 
 
Spectrum 29. 1H NMR of 6-(Furan-2-yl)-8-methyl-9H-purin-2-amine (40). 
 
51 
 
Spectrum 30. 13C of 6-(Furan-2-yl)-8-methyl-9H-purin-2-amine (40). 
 
Spectrum 31. HMQC of 6-(Furan-2-yl)-8-methyl-9H-purin-2-amine (40) 
52 
 
 
Spectrum 32. HMBC of 6-(Furan-2-yl)-8-methyl-9H-purin-2-amine (40). 
 
4.10.  Synthesis of 6,8-di(furan-2-yl)-9H-purin-2-amine (39). 
 
                                                        
A mixture of 6,8-di(furan-2-yl)-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (35b) 
(220 mg, 0.51 mmol), 96% EtOH (10 mL) and 9.6 M HCl (0.55 mL) was stirred at ambient 
temperature until TLC shows complete conversion and neutralized by addition of solid 
KHCO3. The resulting mixture was evaporated in vacuo and the product was isolated by flash 
chromatography on silica gel using Chloroform/MeOH (50:1). 
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Yield 98 mg, (71 %), Yellowish powder. M.p 148 – 151 oC, 
HR-MS: Found 267.080356, caculated value for C13H9N5O2 267.0756. 
1H NMR (DMSO- d6, 200 MHz): δ 6.48 (br s, 2H, NH2), 6.70 - 6.76 (m, 2H, H-4 in furyl), 
7.22 (d, J = 3.2 Hz, H-3 in furyl), 7.73 (d, J = 3.1 Hz, H-3 in furyl), 7.93 – 7.95 (m, H-5 in 
fruyl), 13.1065 (br s, 1H, NH).    
 
 
Spectrum 33. 1H NMR of 6,8-di(furan-2-yl)-9H-purin-2-amine (39). 
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4.11.  Synthesis of 9-Benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a) 
and    7-benzyl-8-chloro-6-(furan-2-yl)-7H-purin-2-amine (42b) 
 
                                                      
Potassium carbonate (83 mg, 0.6 mmol) was added to a stirred solution of  8-chloro-6-(furan-
2-yl)-9H-purin-2-amine (38) (50 mg, 0.2 mmol) in dry DMF (2mL) at ambient temperature 
under nitrogen. After 20 min benzyl chloride (0.036 mL, 0.3 mmol) was added, the resulting 
mixture was stirred for 15 hr, filtered and evaporated. The isomers were separated by flash 
chromatography on silica gel using EtOAc/hexane (3:1). 
9-Benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a) 
Yield 30 mg, (45 %), Yellowish powder. M.p 161 -163 oC, 
1H NMR (DMSO- d6, 300 MHz): δ 5.31 (s, 2H, CH2), 6.75 - 6.77 (br, 3H, NH2 and H-4 in   
furyl), 7.23 – 7.36 (m, 5H, Ph), 7.63 (d, J = 3.3 Hz 1H, H-3 in furyl.), 7.99 (d, J = 0.81 Hz  
1H, H-5 in furyl). 
13C NMR  (DMSO- d6, 75 MHz): δ 46.24 (CH2), 113.44 (C-4 in furyl), 117.32 (C-3 in furyl), 
121.12 (C-5), 127.74, 128.68, 129.68 (CH in Ph), 136.59 (C in Ph), 139.05 (C-4), 145.65 (C-
6), 146.70 (C-5 in furyl), 149.87 (C-2 in furyl), 155.37 (C-8), 161.29 (C-2), 
MS (EI) m/z (rel. %): 327/325 (29/83, M+), 290 (6), 234 (2), 91 (100),  
HR-MS: Found 325.073645, caculated value for C16H12ClN5O 325.0730 
Anal: Found C, 59.46; H, 3.65; N, 21.90. C16H12ClN5O requires C, 58.99; H, 3.71; N, 21.50 
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Spectrum 34. 1H NMR of 9-Benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a). 
 
Spectrum 35. 13C NMR of 9-Benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a). 
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Spectrum 36. HMQC of 9-Benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a). 
 
Spectrum 37. HMBC of 9-Benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a). 
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4.12.  7-benzyl-8-chloro-6-(furan-2-yl)-7H-purin-2-amine (42b) 
Yield  (45 %), Yellowish powder. M.p 159 – 161 oC, 
1H NMR (DMSO- d6, 300 MHz): δ 5.55 (s, 2H, CH2), 6.80 (dd, J = 3.4, 1.8Hz, H-4 in furyl),   
7.24 – 7.36  (m, 5H, Ph), 7.81 (d, J = 3.4 Hz 1H, H-3 in furyl.), 7.87 (br s, 2H, NH2), 8.17 (s,  
H-5 in furyl). 
13C NMR  (DMSO- d6, 75 MHz): δ 49.29 (CH2), 113.99 (C-4 in furyl), 119.97 (C-3 in furyl), 
126.41 (C-5), 127.96, 128.66, 129.51 (CH in Ph), 135.10 (C in Ph), 143.91 (C-4), 147-91 (C-
5 in furyl), 149.36 (C-2 in furyl), 151.31 (C-5), 154.08 (C-2), 155.09 (C-8). 
MS (EI) m/z (rel. %): 325/327 (53/18, M+), 91 (100),  
HR-MS: Found 325.073299, caculated value for C16H12ClN5O 325.0730 
 
 
Spectrum 38. 1H NMR of 7-benzyl-8-chloro-6-(furan-2-yl)-7H-purin-2-amine (42b) 
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Spectrum 39. 13C NMR of 7-benzyl-8-chloro-6-(furan-2-yl)-7H-purin-2-amine (42b) 
 
Spectrum 40. HMQC of 7-benzyl-8-chloro-6-(furan-2-yl)-7H-purin-2-amine (42b) 
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Spectrum 41. HMBC of 7-benzyl-8-chloro-6-(furan-2-yl)-7H-purin-2-amine (42b) 
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4.13.  9-benzyl-6,8-di(furan-2-yl)-9H-purin-2-amine (43a) and 7-benzyl-6,8-
di(furan-2-yl)-7H-purin-2-amine (43b). 
 
                                
Potassium carbonate (80 mg, 0.57 mmol) was added to a stirred solution of  6,8-di(furan-2-
yl)-9H-purin-2-amine (39) (50 mg, 0.19 mmol) in dry DMF (2mL) at ambient temperature 
under nitrogen. After 20 min benzyl chloride (0.035 mL, 0.29 mmol) was added, the resulting 
mixture was stirred for 15 hr, filtered and evaporated. The isomers were separated by flash 
chromatography on silica gel using EtOAc/hexane (3:1). 
4.14. 9-benzyl-6,8-di(furan-2-yl)-9H-purin-2-amine (43a) 
Yield  36mg (53 %), Yellowish powder. M.p 171 – 173 oC, 
1H NMR (DMSO- d6, 300 MHz): δ 5.60 (s, 2H, CH2), 6.67 - 6.69 (m, 3H, NH2 and H-4 in  
furyl), 6.78 (dd, J = 3.3, 1.7Hz, 1H, H-4 in furyl), 7.07 (d, J = 3.5 Hz, 1H, H-3 in furyl.), 7.12 
(d, J = 7.0 Hz, 2H, Ph), 7.25 – 7.29 (m, 3H, Ph), 7.79 (d, J = 3.4 Hz, 1H, H-3 in furyl.), 7.91 
(d, J = 1.0 Hz 1H, H-5 in furyl), 7.99 (s, 1H, H-5 in furyl). 
13C NMR  (DMSO- d6, 75 MHz): δ 46.52 (CH2), 113.11 (C-4 in furyl), 113.41 (C-4 in furyl), 
113.50 (C-3 in furyl), 117.52 (C-3 in furyl), 122.42 (C-5), 127.07, 128.27, 129.56 (CH in Ph), 
137.72 (C in Ph), 142.70 (C-4), 145.04 (C-2 in furyl), 146.02 (C-5 in furyl), 146.08 (C-5 in 
furyl), 146.47 (C-6), 150.34 (C-2 in furyl),   156.20 (C-8), 161.36 (C-2). 
MS (EI) m/z (rel. %): 357  (100, M+), 266 (76), 91 (28).  
HR-MS: Found 357.122012, caculated value C20H15N5O2 357.1226 
Anal: Found C, 67.34; H, 3.70; N, 19.83. C20H15N5O2 requires C, 67.22; H, 4.23; N, 19.60 
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Spectrum 42. 1H NMR of 9-benzyl-6,8-di(furan-2-yl)-9H-purin-2-amine (43a). 
 
Spectrum 43. 13C NMR of 9-benzyl-6,8-di(furan-2-yl)-9H-purin-2-amine (43a). 
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Spectrum 44. HMQC of 9-benzyl-6,8-di(furan-2-yl)-9H-purin-2-amine (43a). 
 
Spectrum 45. HMBC of 9-benzyl-6,8-di(furan-2-yl)-9H-purin-2-amine (43a) 
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4.15. 7-benzyl-6,8-di(furan-2-yl)-7H-purin-2-amine (43b).  
 
Yield  (21 %), Yellowish powder. M.p 173 - 175 oC 
1H NMR (DMSO- d6, 300 MHz): δ 5.65 (s, 2H, CH2), 6.60 (dd, J = 3.1, 1.5Hz, 1H, H-4 in 
furyl),  6.81 (dd, J = 3.3, 1.8Hz, 1H, H-4 in furyl),  7.01 (d, J = 3.2 Hz, 1H, H-3 in furyl.), 
7.27 – 7.35 (m, 5H, Ph), 7.70 (br s, 2H, NH2), 7.77 (s, 1H, H-5 in furyl), 7.94 (d, J = 3.4 Hz, 
1H, H-3 in furyl.), 8.03 (s, 1H, H-5 in furyl). 
13C NMR  (DMSO- d6, 75 MHz): δ 49.07 (CH2), 110.84 (C-4 in furyl), 112.82 (C-4 in furyl), 
113.85 (C-3 in furyl), 119.41 (C-3 in furyl), 128.02 (C-5), 128.56, 129.46, 135.44 (CH in Ph), 
143.44 (C-4), 144.52 (C-2 in furyl), 147.36 (C-5 in furyl), 150.07 (C-5 in furyl), 151.05 (C-6), 
151.16 (C-2 in furyl),   157.57 (C-8),  
MS (EI) m/z (rel. %): 357  (70, M+), 266 (71), 91 (100).  
HR-MS: Found 357.122959, caculated value C20H15N5O2 357.1226. 
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Spectrum 46. 1H NMR of 7-benzyl-6,8-di(furan-2-yl)-7H-purin-2-amine (43b). 
Spectrum 47. 13C NMR of 7-benzyl-6,8-di(furan-2-yl)-7H-purin-2-amine (43b). 
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Spectrum 48. HMQC of 7-benzyl-6,8-di(furan-2-yl)-7H-purin-2-amine (43b). 
Spectrum 49. HMBC of 7-benzyl-6,8-di(furan-2-yl)-7H-purin-2-amine (43b). 
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4.16 9-benzyl-6-(furan-2-yl)-8-methyl-9H-purin-2-amine (44a). 
 
                                              
Potassium carbonate (110 mg, 0.8 mmol) was added to a stirred solution of  6-(furan-2-yl)-8-
methyl-9H-purin-2-amine (40) (55 mg, 0.26 mmol) in dry DMF (2mL) at ambient 
temperature under nitrogen. After 20 min benzyl chloride (0.06 mL, 0.52 mmol) was added, 
the resulting mixture was stirred for 15 hr, filtered and evaporated. TheN-9 isomer was 
isolated by flash chromatography on silica gel using EtOAc/hexane (2:1). 
Yield:  53 mg, (65 %), Yellowish powder. M.p  151 – 155 oC 
1H NMR (DMSO- d6, 300 MHz): δ  2.41 (s, 3H, CH3), 5.30 (s, 2H, CH2), 6.47 (s, 2H, NH2), 
6.72 (dd, J = 3.4, 1.7Hz, 1H, H-4 in furyl),   7.15 – 7.18 (m, 2H, Ph),   7.29 – 7.33 (m, 3H, Ph) 
7.66 (dd, J = 3.4, 2.7Hz, 1H, H-3 in furyl), 7.91 (dd, J = 1.6, 0.9 Hz, 1H, H-5 in furyl).  
13C NMR  (DMSO- d6, 75 MHz): δ 14.85 (CH3), 45.27 (CH2), 113.20 (C-4 in furyl), 116.64 
(C-3 in furyl), 121.86 (C-5), 127.54, 128.42, 129.66 (CH in Ph), 137.55 (C in Ph), 144.86 (C-
6), 146.02 (C-5 in furyl), 150.63 (C-2 in furyl), 151.42 (C-8), 156.14 (C-4), 160.76 (C-2). 
MS (EI) m/z (rel. %): 305 (100, M+),   
HR-MS: Found 305.126800, caculated value for C17H15N5O 305.1277 
Anal: Found C, 66.26; H, 4.80; N, 23.13. C16H12ClN5O requires C, 66.87; H, 4.95; N, 22.94. 
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Spectrum 50. 1H NMR of 9-benzyl-6-(furan-2-yl)-8-methyl-9H-purin-2-amine (44a). 
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Spectrum 51. 13C NMR of 9-benzyl-6-(furan-2-yl)-8-methyl-9H-purin-2-amine (44a). 
 
Spectrum 52. HMQC of 9-benzyl-6-(furan-2-yl)-8-methyl-9H-purin-2-amine (44a). 
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Spectrum 53. HMBC of 9-benzyl-6-(furan-2-yl)-8-methyl-9H-purin-2-amine (44a). 
 
4.17. 9-benzyl-8-ethoxy-6-(furan-2-yl)-9H-purin-2-amine (45) 
                                                        
A mixture of 9-benzyl-8-chloro-6-(furan-2-yl)-9H-purin-2-amine (42a) (87 mg, 0.27 mmol) 
in a 0.2 M solution of sodium ethoxide in ethanol 10 mL was stirred at reflux under N2-atom 
for 15 hr, cooled, and poured into cold saturated aq NH4CL (10 mL). Most of the ethanol was 
removed by evaporation in vacuo and the aqeous mixture was extracted with EtOAc (4 X 20 
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mL). The combined organic layers were dried (MgSO4) and evaporated in vacuo. The product 
was purified by flash chromatography on silica gel eluting with EtOAc/hexame (1:1) 
Yield:  57 mg, (63 %), Yellowish powder. M.p 167 – 170 oC 
1H NMR (DMSO- d6, 300 MHz): δ 1.14 (t, J = 7.1 Hz, 3H, CH3), 4.55 (q, J = 7.1 Hz, 2H, 
CH2), 5.07 (s, 2H, CH2), 6.32 (s, 2H, NH2), 6.70 (dd, J = 3.3, 1.7Hz, 1H, H-4 in furyl), 7.21 – 
7.35 (m, 5H, Ph), 7.54 (d, J = 3.3, 2.7Hz, 1H, H-3 in furyl), 7.89 (s, 1H, H-5 in furyl).  
13C NMR  (DMSO- d6, 75 MHz): δ 15.17 (CH3), 44.39 (CH2), 66.93 (CH2), 113.06 (C-4 in 
furyl), 115.80 (C-3 in furyl), 119.48 (C-5), 127.87, 128.43, 129.53 (CH in Ph), 137.37 (C in 
Ph), 142.41 (C-6), 145.56 (C-5 in furyl), 150.65 (C-2 in furyl), 154.87 (C-4), 156.27 (C-8), 
159.91 (C-2). 
MS (EI) m/z (rel. %): 335 (100, M+), 91(92)   
HR-MS: Found 335.137728, caculated value for C18H17N5O2 335.1382 
Anal: Found C, 64.38; H, 4.68; N, 21.07. C18H17N5O2 requires C, 64.47; H, 5.11; N, 20.88. 
 
Spectrum 54. 1H NMR of 9-benzyl-8-ethoxy-6-(furan-2-yl)-9H-purin-2-amine (45). 
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Spectrum 55. 13C NMR of 9-benzyl-8-ethoxy-6-(furan-2-yl)-9H-purin-2-amine (45). 
Spectrum 56. HMQC of 9-benzyl-8-ethoxy-6-(furan-2-yl)-9H-purin-2-amine (45). 
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Spectrum 57. HMBC of 9-benzyl-8-ethoxy-6-(furan-2-yl)-9H-purin-2-amine (45). 
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